Phenotypes associated with this allele

• Allele Symbol: Flt3^tm1Dosm
• Allele Name: targeted mutation 1, Donald Small
• Allele ID: MGI:3783339
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Flt3^tm1Dosm/Flt3^+ Tg(Mx1-cre)1Cgn/0	B6.Cg-Flt3^tm1Dosm Tg(Mx1-cre)1Cgn	MGI:3819966

Genotype
MGI:3819966

cn1

• Allelic Composition: Flt3^tm1Dosm/Flt3⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: B6.Cg-Flt3^tm1Dosm Tg(Mx1-cre)1Cgn

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:133528 )

• PIPC treated-mice die between 6 and 20 months of age with a median survival time of 10 months

hematopoietic system

enlarged spleen ( J:133528 )

• spleen size in PIPC treated-mice is 2.5-fold greater than normal at 2 months of age and 5-fold greater at 12 months of age

abnormal definitive hematopoiesis ( J:133528 )

• bone marrow and spleen cells of PIPC treated-mice produce more colony forming units-granulocyte/monocyte (CFU-GM) than in wild-type cultures

• however, the number of burst-forming units-erythroid is normal

• cultured bone marrow and spleen cells of PIPC treated-mice produce more immature cells than wild-type cultures

• transplanted bone marrow cells of PIPC treated-mice are capable of producing bone marrow hypercellularity and splenomegaly in recipients

increased pro-B cell number ( J:133528 )

• in PIPC treated-mice

arrested B cell differentiation ( J:133528 )

• B cell maturation in PIPC treated-mice is blocked resulting in decreased pre-B cells and increased pro-B cells compared to in wild-type mice

extramedullary hematopoiesis ( J:133528 )

• in some older PIPC treated-mice

abnormal bone marrow cell morphology/development ( J:133528 )

• bone marrow and spleen cells of PIPC treated-mice produce more colony forming units-granulocyte/monocyte (CFU-GM) in culture compared to wild-type cells

• however, the number of burst-forming units-erythroid is normal

• cultured bone marrow and spleen cells of PIPC treated-mice produce more immature cells than wild-type cultures

increased bone marrow cell number ( J:133528 )

• at 12 months, bone marrow of PIPC treated-mice becomes hypercellular with accumulation of immature myeloid cells and increased mononuclear cell numbers unlike in wild-type mice

• the fraction of undifferentiated or partially differentiated myeloid cells in PIPC treated-mice is increased compared to in wild-type mice

decreased megakaryocyte cell number ( J:133528 )

• at 2 months, megakaryocyte populations in the bone marrow of PIPC treated-mice are reduced compared to in wild-type mice

decreased erythrocyte cell number ( J:133528 )

• at 2 months, erythrocyte populations in the bone marrow of PIPC treated-mice are reduced compared to in wild-type mice

• at 12 months, PIPC treated-mice mice exhibit a decrease in the number of Ter119 cells in the bone marrow

decreased hemoglobin content ( J:133528 )

• at 12 months of age but not 2 months of age in PIPC treated-mice

increased dendritic cell number ( J:133528 )

• in the bone marrow and spleen in PIPC treated-mice

decreased leukocyte cell number ( J:133528 )

• slightly at 2 months of age in PIPC treated-mice

decreased neutrophil cell number ( J:133528 )

• slightly at 2 months of age in PIPC treated-mice

decreased lymphocyte cell number ( J:133528 )

• slightly at 2 months of age in PIPC treated-mice

decreased B cell number ( J:133528 )

• B lymphoid populations in the spleen are reduced compared to in wild-type mice

• at 2 months and 12 months of age, B lymphoid populations in the bone marrow of PIPC treated-mice are reduced compared to in wild-type mice

decreased pre-B cell number ( J:133528 )

• in the bone marrow at 12 months of age in PIPC treated-mice

increased leukocyte cell number ( J:133528 )

• at 12 months of age in PIPC treated-mice

increased granulocyte number ( J:133528 )

• granulocyte and monocyte populations of PIPC treated-mice are expanded in the spleen compared to in wild-type mice

• at 2 months, granulocyte populations in the bone marrow of PIPC treated-mice are expanded compared to in wild-type mice

• at 12 months, the bone marrow of PIPC treated-mice contains more Gr-1 cells than in wild-type mice

increased neutrophil cell number ( J:133528 )

• at 12 months of age in PIPC treated-mice

increased monocyte cell number ( J:133528 )

• granulocyte and monocyte populations from PIPC treated-mice are expanded in the spleen compared to in wild-type mice

• at 2 months, monocyte populations in the bone marrow of PIPC treated-mice are expanded compared to in wild-type mice

• at 12 months, the bone marrow of PIPC treated-mice contains more Mac-1 cells than in wild-type mice

increased hematopoietic stem cell number ( J:133528 )

• the number of Lin^-/low and/or c-KIT+ cells in the bone marrow of PIPC treated-mice is increased at 2 months of age, and even more so at 12 months of age, compared to in wild-type mice

abnormal spleen white pulp morphology ( J:133528 )

• white pulp in PIPC treated-mice contains more immature myeloid less and fewer mature lymphocytes than in wild-type mice

intermingled spleen red and white pulp ( J:133528 )

• at 2 months, areas of myeloproliferation in PIPC treated-mice are found within the red pulp unlike in wild-type mice

• at 12 months, PIPC treated-mice mice exhibit progressive myeloproliferation with expansion mostly of immature myeloid cells in the red pulp unlike in wild-type mice

cellular

delayed cellular replicative senescence ( J:133528 )

• bone marrow cells of PIPC treated-mice can be cultured for longer than wild-type cells without immortalization and with reduced requirement of cytokines

immune system

enlarged spleen ( J:133528 )

• spleen size in PIPC treated-mice is 2.5-fold greater than normal at 2 months of age and 5-fold greater at 12 months of age

increased pro-B cell number ( J:133528 )

• in PIPC treated-mice

arrested B cell differentiation ( J:133528 )

• B cell maturation in PIPC treated-mice is blocked resulting in decreased pre-B cells and increased pro-B cells compared to in wild-type mice

increased dendritic cell number ( J:133528 )

• in the bone marrow and spleen in PIPC treated-mice

decreased leukocyte cell number ( J:133528 )

• slightly at 2 months of age in PIPC treated-mice

decreased neutrophil cell number ( J:133528 )

• slightly at 2 months of age in PIPC treated-mice

decreased lymphocyte cell number ( J:133528 )

• slightly at 2 months of age in PIPC treated-mice

decreased B cell number ( J:133528 )

• B lymphoid populations in the spleen are reduced compared to in wild-type mice

• at 2 months and 12 months of age, B lymphoid populations in the bone marrow of PIPC treated-mice are reduced compared to in wild-type mice

decreased pre-B cell number ( J:133528 )

• in the bone marrow at 12 months of age in PIPC treated-mice

increased leukocyte cell number ( J:133528 )

• at 12 months of age in PIPC treated-mice

increased granulocyte number ( J:133528 )

• granulocyte and monocyte populations of PIPC treated-mice are expanded in the spleen compared to in wild-type mice

• at 2 months, granulocyte populations in the bone marrow of PIPC treated-mice are expanded compared to in wild-type mice

• at 12 months, the bone marrow of PIPC treated-mice contains more Gr-1 cells than in wild-type mice

increased neutrophil cell number ( J:133528 )

• at 12 months of age in PIPC treated-mice

increased monocyte cell number ( J:133528 )

• granulocyte and monocyte populations from PIPC treated-mice are expanded in the spleen compared to in wild-type mice

• at 2 months, monocyte populations in the bone marrow of PIPC treated-mice are expanded compared to in wild-type mice

• at 12 months, the bone marrow of PIPC treated-mice contains more Mac-1 cells than in wild-type mice

abnormal spleen white pulp morphology ( J:133528 )

• white pulp in PIPC treated-mice contains more immature myeloid less and fewer mature lymphocytes than in wild-type mice

intermingled spleen red and white pulp ( J:133528 )

• at 2 months, areas of myeloproliferation in PIPC treated-mice are found within the red pulp unlike in wild-type mice

• at 12 months, PIPC treated-mice mice exhibit progressive myeloproliferation with expansion mostly of immature myeloid cells in the red pulp unlike in wild-type mice

growth/size/body

enlarged spleen ( J:133528 )

• spleen size in PIPC treated-mice is 2.5-fold greater than normal at 2 months of age and 5-fold greater at 12 months of age